ImmunsanT announces end of its global Phase 2 clinical trial for its Nexvax2 drug candidate. Early results indicate gluten-exposure protection similar to placebo.
Continue ReadingImmusanT, Inc., has announced that its therapeutic vaccine candidate, Nexvax2, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
Continue ReadingImmusanT, a clinical-stage company developing Nexvax2®, a therapeutic vaccine intended to protect against the effects of gluten exposure while maintaining a gluten-free diet, presented data at the 2017 International Celiac Disease…
Continue ReadingCurrently, the typical treatment for a patient diagnosed with celiac disease is a strict gluten-free diet for life. Future therapies currently in the pipeline hope to make living with celiac disease less of a burden.
Continue ReadingLast month, the Celiac Disease Foundation had the privilege of sponsoring the 2024 International Celiac Disease Symposium in Sheffield, UK. As the first patient advocate invited to chair and present on a scientific panel, CEO Marilyn Geller co-chaired the End Points in Clinical Trials session with Dr. Francisco Leon, CEO...